The CGT Catapult has shaped a consortium aimed toward advancing the expertise improvement and decreasing prices of cell and gene remedy manufacturing.
The Cell and Gene Remedy Catapult (CGT Catapult) has shaped a consortium of greater than 20 organizations aimed toward advancing the expertise improvement and decreasing prices of cell and gene remedy manufacturing.
In a June 8, 2021 press launch, CGT Catapult introduced the formation of the consortium, which can assess a number of course of analytical applied sciences (PAT) which can be both new or routinely utilized in different industries. Via collaboration and sharing of knowledge, the consortium will act as a catalyst to speed up the event of the mandatory information and understanding at lowered price and funding danger to every group.
“The trade must make a large leap when it comes to analytical functionality and the dynamic use of knowledge to regulate and enhance processes, product, and prices,” mentioned Matthew Durdy, CEO at CGT Catapult, within the press launch. “The approaching collectively of those leaders within the discipline is a vital first step in direction of reaching this.”
“By sharing information and knowledge, the consortium members will have the ability to reap doubtlessly enormous advantages that might result in extra environment friendly processes on this very important discipline,” added Nicholas Medcalf, deputy problem director—Medicines Manufacturing for Innovate UK, within the press launch. “The Cell and Gene Remedy Catapult—supported by Innovate UK—is demonstrating its improbable convening energy in harnessing these main trade gamers for the higher good of UK enterprise and innovation.”
Supply: CGT Catapult